Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG.

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida. 2026 MDA Clinical & Scientific Congress Presentations Oral Presentation: Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44 (March 11, 2026: 12:30 p.m.

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business.

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures including myotonia, muscle function and strength, mobility and patient-reported outcomes Del-desiran showed acceptable safety and tolerability with most adverse events mild or moderate SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1) will be published in the February 19 issue of The New England Journal of Medicine (NEJM). The manuscript is titled "An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.